Drug Discovery Unleashed

Your Drug Discovery Research Partner

Unleashing drug discovery with our expertise in biologically relevant assay systems. Our unique core technology; the Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience) has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline.

Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant.

Think of CETSA as snapshots of true target engagement inside the cell, any time you need them.

Pelago CETSA Team

A wide range of services from early discovery to confirmation

We offer a range of customized services, from confirming target engagement to strengthen target validation and understanding mechanism of action of your compounds. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.

True target engagement assessment

Target
Identification

Lead
generation

Lead
optimization

Preclinical
studies

Clinical
trials

Approved
drugs

Target Identification

CETSA Explore (also known as TPP or PISA) combines the power of Mass Spectrometry with CETSA and allows for unbiased proteome-wide target identification. Being unbiased and hypothesis–free, CETSA Explore can be used for target deconvolution studies for hit compounds from phenotypic screens. Since CETSA can be performed in any sample matrix, the profiling and deconvolution can be conducted directly in disease relevant systems.

Lead Generation

CETSA Navigate HT is a perfect tool to unlock novel chemistry in lead generation programs using compound library sets of up to 500k. Or alternatively use CETSA Navigate for rapid hit confirmation or the CETSA Explore for proteome-wide profiling of lead compounds.

Lead Optimization

CETSA Navigate and Navigate HT are both commonly used within lead optimization programs, with the choice being dependent on the number of compounds tested.  Navigate HT offers greater volumes at lower data point costs in shorter time. Navigate provides a faster assay development and is applicable to a wider range of assay matrices and therefore an ideal format to progress into translational studies. In addition, the CETSA Explore can assess the selectivity profile of the lead series to highlight safety issues that needs to be addressed.

Preclinical Studies

CETSA Navigate’s flexibility makes it the first choice for translations studies where confirming target engagement within tissue samples is required and in patient derived material can provide a vital clue to the drug candidate probable efficacy in human studies.

Clinical Trials

Biomarkers are important to facilitate translation, validate the therapeutic hypothesis and monitor effects in clinical trials and beyond. CETSA Explore can be used to identify novel markers that would not be identified by conventional ‘omics approaches, and if necessary CETSA Navigate or Navigate HT can be used to monitor these in patient samples once the biomarker has been identified.

Approved Drugs

Many drugs have poorly understood, complex and diverse modes of action. CETSA Explore is a powerful tool that provides deep insights into the selectivity and action of drugs. These insights can be used to identify drug repurposing opportunities, drug synergy and new targets.

MORE ABOUT OUR OFFERINGS

Technology
One proven assay. Many flexible formats.

The Cellular Thermal Shift Assay (CETSA) is a well-established, proven and accurate technique for measuring compound binding to target proteins. While CETSA can be adapted for different applications to support any stage of the drug discovery process – from low-throughput confirmation and medium-throughput discovery to proteome-wide exploration – these different methods all rely on the same principle: measurements of the ‘thermal shift’ that occurs when a ligand interacts with a protein.

LEARN ABOUT THE CETSA® TECHNOLOGY

When a compound binds to a protein, the denaturation temperature of that protein can be altered. By applying heat shocks to cells or tissue, then quantifying the difference in the amount of soluble protein in presence compared to absence of the compound, we are able to create snapshots of target engagement under actual physiological conditions. This is how CETSA can be used to assess and quantify compound-protein interactions.

By combining CETSA with functional assays and extended proteomics compound profiling (for example post-translational modification analysis and quantitative proteomics) we generate data that can strengthen the target validation and build confidence earlier in your projects.

Learn more

HOW DO I KNOW IF MY
COMPOUND WILL BE EFFECTIVE?

VISIT PELAGO KNOWLEDGE CENTER

”

At AstraZeneca, we are applying CETSA in hit identification and lead optimization to identify and characterize compounds for a number of novel targets.

Thomas LundbackSenior Director, AstraZeneca

”

Pelago Bioscience offers exceptional technical expertise in all aspects of target deconvolution using CETSA – including study design, sample preparation, LC-MS data acquisition, and statistical processing. Our collaboration always proceeded effectively due to Pelago Bioscience’s responsiveness, scientific commitment, and dedication to clients resulting in delivery of impactful scientific results

Benjamin FontaineScientist, LifeMine Therapeutics

”

CETSA data is a keystone in our SAR analysis, and by assessing cellular engagement of our compounds across multiple cell lines we gain confidence in our project prioritizations.

Peter JoyceCEO & Co-Founder, Grey Wolf Therapeutics

”

Chemoproteomics is like taking a watch to pieces and counting the cogs—it doesn’t tell you which cogs drive which process and how the wider system works. This is why using CETSA MS can add so much value to your target identification studies.

Pär NordlundProfessor & Inventor of CETSA, Karolinska Institute

”

Our small molecule drug discovery project was seeking a robust assay allowing to screen against the target of interest expressed in its natural cellular environment. Pelago Bioscience’s expertise in drug discovery projects, specifically in the CETSA platform and high throughput screens was the key to achieving our goals. We found Pelago’s team to be professional, knowledgeable, flexible and dedicated. We highly recommend Pelgao Bioscience’s team for discovery projects.

Po-Shun LeeChief Medical Officer, Generian

Read AstraZeneca Case Study

About Pelago

”
Using our world leading expertise in CETSA we have created a faster and more efficient drug discovery process. We take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help.

Michael Dabrowski
CEO, Pelago Bioscience
About pelago

Speak to our experts

Learn how Pelago Bioscience can provide unique insights to your project by talking to one of our Drug Discovery experts.

CONTACT US
Contact us